In observance of the Holy Week, the Philippine News Agency’s online news service will be off on March 29, Good Friday, and March 30, Black Saturday. Normal operations will resume on March 31, Easter Sunday.

— The Editors

Complete green lane for local vax producers within 7 days: ARTA

MANILA – Following President Rodrigo Duterte's directive to set up a green lane for faster permit processing of local Covid-19 vaccine manufacturers to reduce dependency on imported jabs, Anti-Red Tape Authority (ARTA) Director General Jeremiah Belgica urged the Food and Drug Administration (FDA) to target its completion within seven working days.

Belgica raised this in a meeting held on April 23 with various pharmaceutical companies.

During the meeting, Higinio Porte of the Philippine Pharmaceutical Manufacturers Association informed the body that at least Unilab and Lloyd Laboratories expressed interest to install a vaccine manufacturing facility. However, he admitted that existing regulatory requirements make it difficult for them to do so.

Belgica previously noted that the creation of a green lane is not a suggestion but a presidential directive that needs to be carried out immediately.

"The President will not settle for anything less. We are in an emergency, every minute counts, so we must act like it is an emergency. The fact that everybody is here means the commitment is there. Ipakita ho natin na kaya natin. Let's make it happen in record time,” Belgica said during an initial briefing on green lane with the Office of the Presidential Adviser on Streamlining of Government Processes (OPASGP), FDA, and other key stakeholders from both public and private sectors.

"By creating the green lane, we prevent more people getting sick, people dying, people losing jobs. I convey my support to FDA, please do it in abnormal times because what you do is for the betterment of the people,” OPASGP Secretary Leoncio “Jun” Evasco added.

ARTA Deputy Director General Ernesto Perez recommended the establishment of a One-Stop-Shop for the convenience of companies willing to invest in local vaccine manufacturing facilities.

"We [ARTA] want more detailed inputs coming from you [local pharmaceutical companies] so whatever your concerns, we will be able to raise these to the government agencies concerned," Perez said.

ARTA will be holding another meeting next week where FDA is expected to present timeline, documentary requirements, and process for green lanes for local manufacturing and importation of vaccines. (PR)

Comments